Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CD69 | Q07108 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PTPRB | P23467 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3825842 | 0.85 | SMN1; SMN2 (0.45) | SMN1; SMN2ALOX15CD69HPGDPTPRB | |
| SCHEMBL26730009 | 0.80 | HPGD (0.51) | SMN1; SMN2ALOX15HPGDPTPRBHSD17B10 | |
| SCHEMBL19555342 | 0.80 | ALOX15 (0.52) | SMN1; SMN2ALOX15CD69HPGDPTPRB | |
| SCHEMBL3923991 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2ALOX15HSD17B10LMNAFFAR1 | |
| SCHEMBL17896563 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2ALOX15CD69HPGDPTPRB | |
| SCHEMBL22601791 | 0.77 | MCL1 (0.49) | ALOX15HPGDPTPRBHSD17B10LMNA | |
| SCHEMBL9503312 | 0.77 | SMN1; SMN2 (0.68) | SMN1; SMN2ALOX15CD69HPGDPTPRB | |
| SCHEMBL21718391 | 0.76 | NQO1 (0.41) | LMNATSHR | |
| SCHEMBL17896565 | 0.76 | SMN1; SMN2 (0.57) | SMN1; SMN2ALOX15HSD17B10LMNAFFAR1 | |
| SCHEMBL28645298 | 0.74 | ALOX15 (0.65) | SMN1; SMN2ALOX15CD69HPGDPTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885797-A1 | AQUEOUS DISPERSIONS OF WATER-SOLUBLE AND/OR WATER-SWELLABLE ANIONIC POLYMERS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2008-02-13 | — | — | EP | claimed |
| WO-2006122947-A1 | AQUEOUS DISPERSIONS OF WATER-SOLUBLE AND/OR WATER-SWELLABLE ANIONIC POLYMERS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-23 | — | — | WO | claimed |
| EP-1858865-B1 | SUBSTITUTED N-SULFONYLAMINOPHENYLETHYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER (US) | 2009-09-16 | — | — | EP | disclosed |
| US-7566739-B2 | Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists | PFIZER INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7514457-B2 | Substituted aryloxymethyl bicyclicmethyl acetamide compounds | PFIZER INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1893583-A1 | SUBSTITUTED ARYLOXY-N-BICYCLOMETHYL ACETAMIDE COMPOUNDS AS VR1 ANTAGONISTS | Pfizer, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1858865-A1 | SUBSTITUTED N-SULFONYLAMINOPHENYLETHYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER INC. (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006129164-A1 | SUBSTITUTED ARYLOXY-N-BICYCLOMETHYL ACETAMIDE COMPOUNDS AS VR1 ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-12-07 | — | — | WO | disclosed |
| US-20060270682-A1 | Substituted Aryloxymethyl Bicyclicmethyl Acetamide Compounds | PFIZER, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006095263-A1 | SUBSTITUTED N-SULFONYLAMINOPHENYLETHYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2006-09-14 | — | — | WO | disclosed |
| US-20060205980-A1 | Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists | PFIZER, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205980-A1 | Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists | CNR1, HVCN1, AVPR1A | SMN1; SMN2 3396/4885ALOX15 2037/4885CD69 1819/4885 |
| US-20060270682-A1 | Substituted Aryloxymethyl Bicyclicmethyl Acetamide Compounds | NR0B1, NR0B2, NR2C2 | SMN1; SMN2 3310/4885ALOX15 3157/4885CD69 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.